In a statement written for the House Energy and Commerce health subcommittee last year, Maisel wrote last year, he stated:“[I]t is critical that the safety and performance of medical devices be improved, that the frequency of medical device malfunctions and adverse events be reduced, and that patients and physicians be adequately informed about device clinical effectiveness and risks in a timely fashion. In short, FDA needs to improve its science-based device assessments and decision-making."
What effects do you think this will have on the medical device industry?

This blog is c0-posted with the Future of Biopharma Blog.
No comments:
Post a Comment